Courses of Malignant Pheochromocytoma
dc.contributor.author | Sisson, James C. | en_US |
dc.contributor.author | Shulkin, Barry L. | en_US |
dc.contributor.author | Esfandiari, Nazanene H. | en_US |
dc.date.accessioned | 2010-06-01T20:27:14Z | |
dc.date.available | 2010-06-01T20:27:14Z | |
dc.date.issued | 2006-08 | en_US |
dc.identifier.citation | SISSON, JAMES C . ; SHULKIN, BARRY L . ; ESFANDIARI, NAZANENE H . (2006). "Courses of Malignant Pheochromocytoma." Annals of the New York Academy of Sciences 1073(1 Pheochromocytoma: First International Symposium ): 505-511. <http://hdl.handle.net/2027.42/73567> | en_US |
dc.identifier.issn | 0077-8923 | en_US |
dc.identifier.issn | 1749-6632 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/73567 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=17102118&dopt=citation | en_US |
dc.description.abstract | Survival of patients with metastatic pheochromocytoma that have exceeded 30 years without therapy to reduce tumors have been reported. We reviewed the records of 38 patients with malignant pheochromocytoma who had received 131 I-metaiodiobenzylguanidine ( 131 I-MIBG) treatments between 1981 and 1996 to evaluate longevity. Survival from diagnosis to last follow-up exceeded 5 years in 21 of 38 (55%) and ≥10 years in 50%. In 17 of 21, the interval from diagnosis to 131 I-MIBG therapy was greater than 5 years. Survival following 131 I-MIBG was ≥5 years in 12 of 17 and ≥10 years in 7 of 17 patients despite continued evidence of excessive circulating catecholamines. Objective responses to 131 I-MIBG therapy were seen in about 30% and were usually of a few years, duration, but one individual exhibited marked reductions in volume and function of tumors that have persisted for 21 years. No feature, including a remission of >5 years following surgical excision, was found to predict prolonged survival. In summary, many patients with malignant pheochromocytoma will follow a course extending over many years. The role of 131 I-MIBG therapy in longevity is uncertain, but this radiopharmaceutical reduces evidence of tumors in some patients. Criteria for selecting patients who will benefit from treatment remain to be determined. | en_US |
dc.format.extent | 148973 bytes | |
dc.format.extent | 3109 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.publisher | Blackwell Publishing Inc | en_US |
dc.rights | 2006 New York Academy of Sciences | en_US |
dc.subject.other | Malignant Pheochromocytoma | en_US |
dc.subject.other | Metaiodobenzylguanidine | en_US |
dc.subject.other | Patient Longevity | en_US |
dc.subject.other | Long-term Survival | en_US |
dc.title | Courses of Malignant Pheochromocytoma | en_US |
dc.type | Article | en_US |
dc.subject.hlbsecondlevel | Science (General) | en_US |
dc.subject.hlbtoplevel | Science | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | Division of Nuclear Medicine, Department of Radiology, University of Michigan Health System, Ann Arbor, Michigan 48109, USA | en_US |
dc.contributor.affiliationum | Division of Endocrinology and Metabolism, Department of Internal Medicine, University of Michigan Health System, Ann Arbor, Michigan 48109, USA | en_US |
dc.contributor.affiliationother | Division of Nuclear Medicine, Department of Radiological Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee 38105, USA | en_US |
dc.identifier.pmid | 17102118 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/73567/1/annals.1353.053.pdf | |
dc.identifier.doi | 10.1196/annals.1353.053 | en_US |
dc.identifier.source | Annals of the New York Academy of Sciences | en_US |
dc.identifier.citedreference | Traub, Y.M. & J.B. Rosenfeld. 1970. Malignant pheochromocytoma with pleural metastasis of unusually long duration. Chest 58: 546 – 550. | en_US |
dc.identifier.citedreference | Remine, R.H. et al. 1974. Current management of pheochromocytoma. Ann. Surg. 179: 740 – 747. | en_US |
dc.identifier.citedreference | Van den Broek, P.J. & J. De Graeff. 1978. Prolonged survival in a patient with pulmonary metastases of malignant pheochromocytoma. Neth. J. Med. 21: 245 – 247. | en_US |
dc.identifier.citedreference | Abemayor, E. et al. 1980. Multiple sequential pulmonary resections for metastatic pheochromocytoma with long-term survival. Am. J. Surg. 140: 696 – 697. | en_US |
dc.identifier.citedreference | Brennan, M.F. & H.R. Keiser. 1982. Persistent and recurrent pheochromocytoma: the role of surgery. World J. Surg. 6: 397 – 402. | en_US |
dc.identifier.citedreference | Mornex, R et al. 1992. Malignant pheochromocytoma: a series of 14 cases observed between 1966 and 1990. J. Endocrinol. Invest. 15: 643 – 649. | en_US |
dc.identifier.citedreference | Yoshida, S.M. et al. 2001. Twenty-six-years' survival with multiple bone metastasis of malignant pheochromocytoma. Arch. Orthop. Trauma. Surg. 121: 598 – 600. | en_US |
dc.identifier.citedreference | Young, A.L. et al. 2002. Familial malignant catecholamine-secreting paraganglioma with prolonged survival associated with mutation in the succinate dehydrogenase B gene. J. Clin. Endocrinol. Metab. 87: 4101 – 4105. | en_US |
dc.identifier.citedreference | Marnix, G.E.H. et al. 2005. Repeated [ 131 I]metaiodobenzylguanidine therapy in two patients with malignant pheochromocytoma. J. Clin. Endocrinol. Metab. 90: 5888 – 5895. | en_US |
dc.identifier.citedreference | Bomanji, J.B. et al. 2003. Treatment of neuroendocrine tumours in adults with 131 I-MIBG therapy. Clin. Oncol. 15: 193 – 198. | en_US |
dc.identifier.citedreference | Van Heerden, J.A. et al. 1990. Long-term evaluation following resection of apparently benign pheochromocytoma(s)/paraganglioma(s). World J. Surg. 14: 325 – 329. | en_US |
dc.identifier.citedreference | Amar, L. et al. 2005. Year of diagnosis, features at presentation, and risk of recurrence in patients with pheochromocytoma or secreting paraganglioma. J. Clin. Endocrinol. Metab. 90: 2110 – 2116. | en_US |
dc.identifier.citedreference | Khoram-Manesh, A. et al. 2005. Long-term outcome of a large series of patients surgically treated for pheochromocytoma. J. Intern. Med. 258: 55 – 66. | en_US |
dc.identifier.citedreference | Shapiro, B. et al. 1991. Radiopharmaceutical therapy of malignant pheochromocytoma with [ 131 I]metaiodobenzylguanidine: results from ten years of experience. J. Nucl. Med. Biol. Med. 35: 269 – 276. | en_US |
dc.identifier.citedreference | Sisson, J.C. et al. 1999. Treatment of malignant pheochromocytomas with 131-I metaiodiobenzylguanidine and chemotherapy. Am. J. Clin. Oncol. 22: 364 – 370. | en_US |
dc.identifier.citedreference | Koh, K-C. et al. 1997. The treatment of malignant pheochromocytoma with iodine-131 metaiodobenzylguanidine ( 131 I-MIBG): a comprehensive review of 116 reported patients. J. Endocrinol. Invest. 20: 648 – 658. | en_US |
dc.identifier.citedreference | Sisson, J.C. 2002. Radiopharmaceutical treatment of pheochromocytoma. Ann. N.Y. Acad. Sci. 970: 54 – 60. | en_US |
dc.identifier.citedreference | Safford, S.D. et al. 2003. Iodine-131 metaiodobenzylguanidine is an effective treatment for malignant pheochromocytoma and paraganglioma. Surgery 134: 956 – 963. | en_US |
dc.identifier.citedreference | Rose, B. et al. 2003. High-dose 131 I-metaiodobenzylguanidine therapy for 12 patients with malignant pheochomocytoma. Cancer 98: 239 – 248. | en_US |
dc.identifier.citedreference | Ohta, S. et al. 2005. Downregulation of metastasis suppressor genes in malignant pheochromocytoma. Int. J. Cancer 114: 139 – 143. | en_US |
dc.identifier.citedreference | Rooijens, P.P. et al. 2004. The significance of angiogenesis in malignant pheochromocytoma. Endocr. Path. 15: 39 – 45. | en_US |
dc.identifier.citedreference | Brouwers, F.M. et al. 2005. Low molecular weight proteomic information distinguishes metastatic from benign pheochromocytoma. Endocr. Relat. Cancer 12: 263 – 272. | en_US |
dc.identifier.citedreference | Eisenhofer, G. et al. 2005. Biochemical and clinical manifestations of dopamine-producing paragangliomas: utility of plasma methoxytyramine. J. Clin. Endocrinol. Metab. 90: 2068 – 2075. | en_US |
dc.identifier.citedreference | Sawka, A.M. et al. 2003. A comparison of biochemical tests for pheochromocytoma: measurement of fractionated plasma metanephrines compared with the combination of 24-hour urinary metanephrines and catecholamines. J. Clin. Endocrinol. Metab. 88: 553 – 558. | en_US |
dc.identifier.citedreference | Eisenhofer, G. et al. 2003. Biochemical diagnosis of pheochromocytoma: how to distinguish true- from false-positive test results. J. Clin. Endocrinol. Metab. 88: 2656 – 2666. | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.